NCT06513455View on ClinicalTrials.gov

Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

Irinotecan liposome（40mg/m2）

irinotecan Liposome was administered 40mg/m2, D1，iv. q2w

DRUG

Nab-paclitaxel

Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w

DRUG

Gemcitabine

gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w

DRUG

Irinotecan Liposome（60mg/m2）

irinotecan Liposome was administered 60mg/m2, D1，iv. q2w

All Listed Sponsors
lead

Harbin Medical University

OTHER